• SideChannel recently released its financial results for Q1 2023, recognizing $1,546,000 in revenue, a 48% year-over-year increase
• The company also ended the fiscal quarter with $2,553,000 in cash, having spent about $480,000 to offset R&D and marketing expenses
• SideChannel is in the business of providing cybersecurity leadership and program development through its team of virtual Chief Information Security Officers (“vCISOs”)
• The company has also developed Enclave, a micro-segmentation software that recently received FIPS 140 certification, opening the door for SideChannel to pursue federal and state contracts and further increase cybersecurity revenue

SideChannel (OTCQB: SDCH), a company focused on delivering cybersecurity programs as a service and complimentary solutions to small and middle-market companies that have long been priced out of cybersecurity solutions, recently announced its financial results for the quarter ended December 31, 2022 (“Q1 2023”). The company recognized a 48% year-over-year revenue growth from $1,048,000 in Q1 2022 to $1,546,000 in the just-ended quarter (https://ibn.fm/ZQIlD). Furthermore, the Q1 2023 revenue represented a 26% quarter-over-quarter growth from Q4 2022 figures.

In addition, the company closed off the year with $2,553,000 in cash, having used about $480,000 in the just-ended quarter to offset operational expenses. More specifically, these expenses included investments in a few growth initiatives, including research and development (“R&D”) expenditure to advance its micro-segmentation software Enclave as well as sales and marketing to acquire new clients, according to SideChannel CFO Ryan Polk. Ryan was speaking in the company’s financial-results conference call hosted February 13. A recording of the call is available on the company’s website at https://ibn.fm/YxdC4 (registration required).

“An increasing number of emerging and mid-market companies are recognizing the need for more robust cybersecurity programs to reduce the risks impacting their business, whether it is from increased regulation, customer demands, or Board-level oversight,” CEO Brian Haugli conveyed in a news release announcing the financial results. “These companies turn to SideChannel to provide cybersecurity leadership and program development through our team of virtual Chief Information Security Officers (‘vCISOs’). In the last twelve months, revenue from our vCISO practice has increased 66%.”

The company intends to continue delivering on its strategy, which emphasizes growing vCISO relationships while adding complimentary products, cybersecurity services, and privacy services to help its clients cost-effectively reduce risk. SideChannel recognizes that small and middle-market companies face growing needs for cybersecurity through software and services. However, the rising costs and rapid turnover of Chief Information Security Officers (“CISOs”) leave them priced out of the market for the talent they truly need. In addition, CISOs are burning out and are looking for a better way to practice the profession they love and bring real value to companies in need of their services.

“We, as SideChannel, marry these two,” said Haugli in the conference call. “We offer cybersecurity programs as a service via senior experienced CISOs to those mid-market companies and emerging tech and startups on a fractional, cost-effective basis. This offers SideChannel’s customers unparalleled expertise and support, but at a price that is appropriate to their budgets. Moreover, they can also benefit from our expansive team, deep vertical expertise, and the opportunity to source from a wide array of software and other tools from across the industry.”

One software SideChannel’s clients can benefit from is Enclave. According to Haugli, this micro-segmentation application reduces risk, enhances productivity, and makes zero-trust a reality. “We can deploy Enclave in a variety of ways, either through direct license sales or via a managed service. And the focus shift on Enclave is not just to deliver encryption, but also deliver through micro-segmentation more than just encryption itself,” Haugli explained.

Enclave, Haugli intimated, is now a FIPS 140-certified product. (Federal Information Processing Standards or FIPS define the data security and computer system standards that an organization must heed. One of these standards, the FIPS 140, requires the system to have at least one working encryption algorithm https://ibn.fm/dg3tX. The certification clears SideChannel to pursue federal and state contracts, which require FIPS 140 compliance, and be able to sell Enclave to government entities. Thus, looking ahead, SideChannel is well positioned to grow revenue from cybersecurity software even further, considering that Q1 2023 revenue from this stream witnessed a 28% year-over-year growth, according to Ryan.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• EverGen Infrastructure CEO, Chase Edgelow recently joined a webinar hosted by Adelaide Capital to provide investors and stakeholders with an update on the company’s operations
• Edgelow elaborated on the company’s portfolio, including its 4 existing revenue generating assets, 2 projects currently under construction as well as its Ontario-based Greenfield project, Project Radius
• By 2Q 2023, EverGen anticipated that the completion of its RNG projects would drive gross generating capacity to 240,000 GJ/annum, whilst growing EBITDA by $5-7m per year
• In the longer term, successful execution on EverGen’s Ontario-based Greenfield project could see the company expand its RNG production by as much as 1.7 million GJ/year

British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), has long held aspirations of transforming into Canada’s leading RNG infrastructure platform, in the process securing strong long-term contracted cash flows. The company today operates 4 revenue generating assets across 3 key regions in Canada, alongside 2 RNG projects currently under construction as well as one Ontario-based project in development. EverGen Infrastructure Corp CEO, Chase Edgelow recently participated in a webinar hosted by Adelaide Capital to provide investors with an update on the company’s ongoing operations as well as their prospects going forward (https://ibn.fm/XPI4q).

Edgelow revealed that following the completion of its two RNG projects currently under construction, namely Fraser Valley Biogas and GrowTEC, both of which are anticipated to be ready as of the end of Q1 2023–EverGen Infrastructure will see its built-up capacity expanded to 240,000 gigajoules of RNG per annum, a growth which could drive an additional $5-7 million dollars worth of EBITDA per year for the company. Meanwhile and on a longer-term basis, EverGen is simultaneously pursuing the expansion of all its ongoing projects through a broad-based $45m pre-funded capital expenditure plan; successful completion of all its initiatives will see the company grow its cumulative gross generating capacity to 480,000 gigajoules of renewable natural gas on an annual basis, whilst simultaneously tripling EverGen’s current run-rate EBITDA.

Over 37 billion tons of carbon emissions are released into the world’s atmosphere on a yearly basis (https://ibn.fm/uMUVl); in one recent study, BNY Mellon estimated that over $100 trillion in investments was necessary to tackle emissions if the world was to successfully achieve its stated Net Zero ambitions by 2050 (https://ibn.fm/XMRTj). Today and with over $1 trillion being invested annually into building out clean energy capacity (https://ibn.fm/0MS7Z), EverGen Infrastructure Corp finds itself operating at the center of what former Bank of England Governor, Mark Carney, referred to as the “greatest commercial opportunity of our age.”

EverGen Infrastructure’s path to becoming one of Canada’s largest RNG platforms owes its origins to the province of British Columbia’s decision in March 2017 to amend the Greenhouse Gas Reduction Regulation. The amendment, which sought to increase the production and use of renewable gas as well as green and waste hydrogen in British Columbia to simultaneously generate jobs and economic opportunities while reducing GHG emissions, has played a significant role in driving the sector’s growth prospects in recent years.

Since starting its operations and expanding its presence in British Columbia to three operating assets, EverGen Infrastructure made a bold decision to expand its presence nationwide over the past year. In 2022, the company broadened its Canadian footprint by acquiring a 67% stake in GrowTEC, an Alberta-based biogas project. EverGen would subsequently go on to purchase a 50% ownership in a large joint venture consisting of three high-quality, on-farm RNG projects in Ontario dubbed Project Radius.

It is within the latter Greenfield project that EverGen Infrastructure could stand to make its fortunes. Project Radius, located in southern Ontario, is a late-development-stage portfolio of three high-quality, on-farm RNG projects, collectively capable of producing ~1.7 million GJ/year of RNG that will contribute to the reduction of emissions from agricultural operations in southern Ontario. Each of the three projects is expected to produce ~550,000 GJ/year and will be constructed throughout 2023 and 2024.

“The acquisition of Project Radius provides a foothold in Ontario – a new and strategic jurisdiction in which EverGen can continue to participate in the consolidation and growth of the RNG industry in the near-term, as well as benefit from project economics in line with or exceeding those we have seen with our initial projects,” said Chase Edgelow, CEO of EverGen (https://ibn.fm/VBO5H). “Working alongside Northeast to advance the projects, EverGen will deliver on our platform expansion commitments with the potential to exceed 1,000,000 GJ of RNG production annually.”

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Lexaria’s 2022 R&D efforts saw high levels of success, establishing the company as one of the world’s leaders in the investigation of CBD for controlling human blood pressure and, separately, demonstrating performance enhancements compared to one of the world’s leading anti-seizure medications
• During Q1 2023, Lexaria expects to provide additional results from its hypertension study HYPER-H21-4; complete dosing in the company’s animal dementia and diabetes studies; complete dosing in the human nicotine study NIC-H21-1; and submit and publish additional results in research journals
• Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. In a letter to shareholders last month, Lexaria CEO Chris Bunka provided a thorough strategic update and insight into the company’s plan moving forward.

Mr. Bunka expressed how the current state of the economy has presented challenges to companies, especially during 2022. Still, Lexaria has navigated these challenges well by focusing on the things it can control, such as applied R&D designed to entice others to work with the company commercially. Despite inflation running at a 40-year high and 2022 stock markets experiencing the longest protracted decline since 2008, Lexaria is forging ahead – increasing staff and successfully handling an unprecedented volume of work (https://ibn.fm/K4s9R).

During 2022, Lexaria’s R&D pursuits were a success, firmly establishing the company as one of the world’s leaders in the investigation of cannabidiol (“CBD”) for controlling human blood pressure and demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications. Lexaria expects that 2023 will be full of additional R&D developments.

Lexaria’s expectations for Q1 2023 include the following:

• Additional results from hypertension study HYPER-H21-4
• Dosing completion in the company’s animal dementia study
• Dosing completion in the company’s animal diabetes study
• Dosing completion in human nicotine study NIC-H21-1
• Submissions and publishing of additional results in research journals

Also in 2023, Lexaria expects to file its Investigational New Drug (“IND”) application and receive approval from the US Food and Drug Administration (“FDA”) to commence the IND clinical study. The study will be a major step in the company’s maturation as a pharmaceutical company and will be its primary research focus once it commences.

Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide. The technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine, and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. It is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, oral suspensions and more.

DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients – increasing effectiveness and improving the way APIs enter the bloodstream. The benefits of DehydraTECH include faster delivery of the drug, increased bioavailability, increased brain absorption, improved drug potency, reduced drug administration costs, and masks unwanted taste, removing the need for additional sweetening ingredients.

Since 2016, Lexaria’s DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and, reduce the time of onset from one to two hours to just minutes.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Export services under NAFTA, mainly covering transportation, travel, business, and financial services, increased from $14.7 billion in 1999 to $30.4 billion in 2021
• With the transition from NAFTA to USMCA, trade in goods and services is set to see a spike from 2022 going forward, and Fr8Tech expects to capitalize on this
• Freight Technologies Inc., with its superior freight platform for North American cross-border shipping, yielded a 45% YOY revenue growth for Q2 2022, which it looks to surpass in the subsequent quarters of the current financial year
• With trucks moving about 70% of North American surface trade by value, trucking companies, Fr8Tech included, are set to be the biggest beneficiaries with the USMCA, enjoying benefits such as reduced administrative burdens and faster shipping times
• The USMCA’s objective is to support a mutually beneficial trade that seeks to achieve more accessible markets, fairer trade, and economic growth in North America. Fr8Tech looks to capitalize on opportunities that present themselves to not only create shareholder value but also grow its brand equity and realize its short-term and long-term objectives

According to the United States Census Bureau, the export of services under the North American Free Trade Agreement (“NAFTA”), mainly covering transportation, travel, business, and financial services, increased from $14.7 billion in 1999 to $30.4 billion in 2021. The same applies to the trade of services between the U.S. and Canada. With the transition from NAFTA to the United States-Mexico-Canada Agreement (“USMCA”), it is projected that trade in goods and services in the region will not be altered. The study projects that operations in this sector will soar as trade among the three countries grows (https://ibn.fm/2BEFI).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an enterprise developing solutions to optimize and automate the supply chain process and offering a platform for B2B cross-border shipping in the NAFTA (now USCMA) region looks to capitalize not just on the smooth transition, but also the relatively unaltered trade in goods and services to grow its market share and achieve its revenue objectives. This level of focus has allowed the company to achieve a 45% year-over-year (“YOY”) revenue growth for the second quarter of the 2022 financial year, which It looks to surpass in the subsequent quarters of the current financial year (https://ibn.fm/IDih3).

The shift from NAFTA to USMCA came in the wake of proposed amendments to the initial agreement among the member countries. These changes would be founded on the basic principles of free trade provided in NAFTA but modernizing and adjusting some components. For some sectors, particularly the energy sector, the proposed changes received heavy politicization and significant proposed adjustments. However, the transport sector was set to receive more support from the member states. The primary beneficiaries would be logistics services companies and transport modes, who would enjoy a reduced administrative burden and faster shipping times, translating into more revenues and fewer overheads.

With trucks moving about 70% of North American surface trade by value, trucking companies are set to be the biggest beneficiaries with the USMCA (https://ibn.fm/nCMq0). Fr8Tech, with its Fr8App, a B2B marketplace powered by Artificial Intelligence (“AI”) and Machine learning, looks to make cross-border shipping simple, safe and affordable. With the USMCA, the company looks to scale up its operations, grow its customer base and achieve even more growth going forward.

The objective for USMCA, as was the case with NAFTA, is to support mutually beneficial trade leading to more accessible markets, fairer trade, and robust economic growth in North America. It is specifically intended to grow various regional industries and sectors, and transportation is one of this transition’s primary beneficiaries. Fr8Tech recognizes this opportunity and is looking to bank on it to create shareholder value, grow its brand equity, and realize its short-term and long-term objectives.

For more information, visit the company’s website at www.Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Alternative Products Expo has just announced its next show, which will take place on March 3-5, 2023, in the beautiful city of Fort Lauderdale, Florida. This one-of-a-kind trade show promises to provide attendees with a unique experience that breaks away from the monotony of traditional events. It’s a must-attend for anyone in the smoke shop and counterculture industry.

Known for short as Alt Pro Expo, this event has its roots in the Vape and CBD world and has since expanded to include a plethora of industries. With over 200 exhibitors representing various product categories, such as Vape, CBD, Hemp, Delta-8, Nicotine Alternatives, Kratom, Extracts, Functional Beverages, tinctures, edibles, herbal products, mood enhancers, energy boosters, dietary supplements, and much more, there’s something for everyone to discover.

According to Jason Monti, the event’s co-founder, “ALT PRO Expo is more than just a trade show. It’s a platform for all counterculture professionals looking to expand or tap into this growing market.” And with thousands of registered buyers, prominent brands, and influential media partners participating, it’s an incredible opportunity for anyone looking to make new connections or showcase their products and services.

But the excitement doesn’t stop there. Florida is home to some of the most notable Alternative Product companies, and Fort Lauderdale, in particular, is a thriving hub for the counterculture industry. Attendees can take advantage of the many recreational activities in the area, such as boating, fishing, and sunbathing, making Alt Pro Expo the ideal destination for a productive and enjoyable trade show experience.

So mark your calendars and get ready to discover the latest and greatest in alternative products at the Alt Pro Expo. It’s an event you won’t want to miss!

For more information, please visit https://altproexpo.com/

Mining Journal Select Show on March 27-28th, 2023. An exclusive lineup of presenters will pitch their businesses in front of industry leaders and investors and get an opportunity for one-on-one meetings and personalized discussions with these eminent investment groups.

These mining companies presenting at Mining Journal Select are selected by the Mining Journal Research & Intelligence Team, who conduct research and analysis to shortlist a curated list of companies with exceptional potential and prospects. Investors looking for robust investment avenues can leverage this forum to discover aspiring mining businesses with exceptional qualities.

Aspiring and veteran miners and mining companies with bright and innovative ideas get to pitch their business prospects in front of an audience of over 400 institutional and retail investors. In addition, investors will be able to hold personalized meetings to analyze the mining presenting companies up close and personal. Presenting companies and other attendees associated with allied industries can participate in the 20+ pre-booked meetings to discuss their ideas directly with investors, as they connect and develop further networking ties over the two days of the event.

Mining Journal Select is one of the leading and established brands in the mining arena. Hence, attendees who are a part of the event have the opportunity to leverage the contacts and reach of Mining Journal and MiningNews.net. The company has an expansive reach with a global audience of 100,000 elite class and more than 1.5 million retail investors that were targeted via a CEO video interview.

Attendees get a chance to meet outstanding miners and come across new development projects in the mining segment. The event showcases a sophisticated audience that will get access to branded pods with screens to host the investor meets. About 800+ meetings between investors and mining companies will be hosted in the two days of the event. A dedicated concierge of experts focused on their jobs, will conduct and deliver 20+ meetings in an organized manner for each mining organization.

Some of the confirmed speakers for the upcoming event include:

• Alex Tsukernik, President & CEO Nova Royalty
• Barry Cahill, Executive Director, Cyprium Metals
• Brett Heath, President and CEO, Metalla Royalty & Streaming
• Bruce Griffin, Executive Chair, Sheffield Resources
• David Harquail, Chairman, Franco Nevada
• Mark Selby, Chairman & CEO, Canada Nickel
• … plus much more

In addition, 4 expert panel sessions will offer insights and support the communication and networking between mining companies and investors.

Join in for 14+ hours of interactive mining discussions, networking and interactions that will pave way for long-term business ties.

To learn more, please visit (https://ibn.fm/xSYj2).

• SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females”
• Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD
• Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease
• Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug approval pathway

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued US Patent 11,491,120 by the US Patent and Trademark Office (“USPTO”) (https://ibn.fm/rMLOR). The patent, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females”, enables SILO to expand its intellectual property and technology rights for treating rare stress-related medical conditions.

SPC-15 is a targeted prophylactic ketamine formulation used in a novel protocol to treat and prevent stress-induced affective disorders, including PTSD.

“After a comprehensive review by USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its market potential for anxiety, PTSD, and related disorders,” said SILO Chief Executive Officer Eric Weisblum.

SILO collaborates with first-in-class research partners at leading universities to advance research in the medical and psychedelic sectors. The company holds an option to license certain assets currently under development by Columbia University through a commercial evaluation license agreement between both parties. Other drugs in the company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, and SPC-14 as a treatment for Alzheimer’s disease.

Several therapeutics developed by the company may qualify for the FDA’s streamlined 505(b)(2) regulatory drug approval pathway. Drugs that qualify under the 505(b)(2) pathway may be exempted from conducting repeat studies previously performed on tested drugs, enabling the company to reduce expenses and speed up the time to market (https://ibn.fm/BiKBw). Other benefits include lower treatment risk due to previous drug approval and the potential to qualify for 3-7 years of market exclusivity.

Silo Pharma Inc. merges traditional therapeutics with psychedelic research to develop innovative therapeutics for underserved markets, including PTSD, fibromyalgia, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, and other rare neurological conditions. The company collaborates with top universities and research institutions to develop therapeutics that can improve patient outcomes and potentially transform the healthcare industry.

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• BiondVax Pharmaceuticals is promoting preclinical results of its lead “biobetter” NanoAb drug candidate for conveniently proactively preventing COVID
• The company’s CEO recently presented the data at the annual BIO CEO & Investor Conference in New York, as well as updates on the company’s pipeline for treating autoimmune diseases such as psoriasis, asthma, psoriatic arthritis and macular degeneration
• Monoclonal antibody-based drug product Evusheld recently lost its EUA authorization as a COVID preventative after FDA findings that it insufficiently protects against the current wOmicron sub-variants, eliminating the only preventative option for vaccine-intolerant patients
• BiondVax nano-sized antibodies may provide superior responses to COVID both for current and potential future subvariants of the virus

Pioneering immunotherapy developer BiondVax Pharmaceuticals (NASDAQ: BVXV) is seeing convincingly positive outcomes for preventing and arresting disease in COVID patients during an ongoing preclinical in vivo study, even as continually evolving variants of the COVID virus are shutting down emergency authorization-approved (“EUA”) avenues of treatment that may no longer be effective.

Last month, drug ineffectiveness led the U.S. Food and Drug Administration (“FDA”) to revise its Emergency Use Authorization (“EUA”) for the monoclonal antibody prophylactic, Evusheld, removing its availability  for people who have a history of severe adverse reactions to vaccines similar to the COVID vaccine or who otherwise may not respond favorably to the COVID vaccine because of an immunocompromised condition (https://ibn.fm/AFJtC).

While Evusheld may return to EUA status in the future if the combined frequency of the extant SARS-CoV-2 variants fall back within the FDA’s standards range for susceptibility to the prophylactic (preventative) drug treatment, for now Evusheld’s sidelining essentially leaves immunocompromised people essentially “on their own against COVID-19,” as Time magazine reported, because Evusheld’s monoclonal antibody product was the only option for pre-exposure prophylaxis (https://ibn.fm/3xfTd).

However, BiondVax’s development of a nano-sized antibody (NanoAb), that to date has shown neutralization of all relevant Omicron subvariants, is generating excitement as a potential superior prophylactic approach to COVID prevention  such as Evusheld’s solution. At-risk groups, such as the elderly and people with comorbidities, may proactively be able to protect themselves through the company’s conveniently self-administered inhaled NanoAb therapy.

BiondVax enjoys exclusive agreements with the Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”) to collaborate on the development and commercialization of innovative COVID-fighting NanoAbs, also known as VHH-antibodies. The NanoAbs have neutralized the SARS-COV-2 virus, in-vitro, at drug concentrations about 100 times lower than those required by currently commercially available monoclonal antibodies (“mAbs”), which may lead to increased efficacy, reduced side effects, and allow production at a lower cost, according to the companies (https://ibn.fm/HD6ue).

“NanoAb therapeutics have the potential to quickly and effectively address new variants,” BiondVax CEO Amir Reichman told shareholders in December (https://ibn.fm/NxXuO). “Our collaborators at MPI and UMG have generated libraries each with (about) 300 million COVID-19 NanoAb candidates, as compared to mAb libraries that contain only thousands of options. Thus, as new variants emerge, we would expect to be in a position to rapidly develop a new neutralizing NanoAb.”

The nanoparticle nature of the company’s leading candidate has made possible administration through an innovative, inhaled treatment that may provide a desirable alternative to available therapies for treating patients after they have become ill with the virus, as well as a preventative prophylactic providing protection prior to exposure. Reichman provided a presentation on BiondVax’s successful preclinical results this month at the annual BIO CEO & Investor Conference in New York, including discussion of the company’s “biobetter” NanoAb R&D pipeline for developing novel treatments for autoimmune diseases such as psoriasis, asthma, psoriatic arthritis and macular degeneration.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

Investors, small-cap and micro-cap businesses are invited to attend the virtual edition of the MicroCap Rodeo’s 3rd Annual Winter Wonderland Best Ideas Conference. The event, being organized in association with Issuer Direct, will be held Feb. 21-24, 2023. The conference format is designed based on the successful implementation of the last eight conferences which were a mix of in-person as well as virtual events.

The MicroCap Rodeo, a leading conference production in the microcap space, has pioneered several networking sessions that feature keynote speakers and offers a robust platform for company presentations for company management and marquee investors. Issuer Direct is a top communications and compliance company, that provides solutions for both public and investor relations professionals.

The conference will span 4 days featuring company presentations from more than 35 publicly traded microcap and small-cap companies. In these 25-minute presentations that will be held on Feb. 21-22, leading industry leaders and veterans will offer their valuable insightful views and vision for their respective companies. They will also discuss their strategies, the future course of action, key business challenges and current market scenario.

On Feb. 23-24, 2023, 1-on-1 meetings will be held among qualified institutional investors and the leadership of presenting companies where they get the opportunity to build lasting relationships, explore synergies, and discuss business collaborations.

The main agenda of the conference is to offer business opportunities to the microcap spectrum industries while directing investors to discover new business avenues.  These conferences boost business productivity and foster growth and expansion in targeted markets. There is lucrative exchange of views and knowledge-sharing among the seasoned attendees, businesses and industry leaders.

The MicroCap Rodeo conferences offer a forum where microcap companies and investors can engage in the critical interaction that can be so evasive in the sector. As the event is being conducted on a virtual forum, the conference can have a greater outreach.

Stalwarts and experts from far and wide can join the conference to impart their knowledge and ideas to the attendees. Also, as the conference will be attended by a wide gamut of participants, it will offer greater sales and trading support to the microcap community.  Executives and managers of futuristic microcap companies will be duly recognized on this forum. Attendees can leverage the high-quality networking that will strengthen their networking ties and offer new business opportunities.

To learn more, please visit https://ibn.fm/6Uh0h.

• Adoption of zero-emission vehicles accelerated across almost all markets and vehicle segments in 2022 and will continue on the back of increasing government regulation and incentives
• Power inverters, irreplaceable power conversion tech, has received a meaningful upgrade with Hillcrest’s ZVS inverter technology that improves operating power and efficiency
• Hillcrest anticipates commitments for commercial revenue this year from its inverter as it expands into multiple other areas where the technology is highly applicable

New technologies are always accompanied by unforeseen challenges, especially for the EV space as it is becoming more and more pronounced. There was a time when people thought the idea of a horseless carriage moving around was impossible. Ironically, electric vehicles came about before those powered by gasoline. At the time, gasoline was cleaner and more reliable, so electrics disappeared from the market. With the outset of the new electric vehicle revolution, questions have abounded about a slew of topics, such as safety, range anxiety, and charging infrastructure. Experts are still trying to square circles regarding who will pay for electric grid upgrades, while others like Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) emerge on the scene with innovations tackling heat and power issues that sap efficiency from EVs.

Whether or not the world reaches its net-zero-emission targets for vehicles in the next dozen years or not is up for debate, but there is no doubt that the day of electrification is upon us. According to strategic research provider BloombergNEF, adoption of ZEVs (zero-emission vehicles) accelerated across almost all markets and vehicle segments in 2022. The result? 1.7 million fewer barrels of oil used each day.

BNEF estimated that EV sales increased from 6.6 million units in 2021 to top 10 million for the first time. In  2022, the total value of global EV sales surpassed the $1 trillion mark. The rise in adoption is supported nearly universally by governments aiming to slash carbon emissions, including the Canadian government officially getting on board late in 2022, launching regulations that will phase out sales of passenger cars and light commercial vehicles that emit emissions starting in 2035.

The good thing for consumers is that innovation is making electric cars and trucks better at the engineering level. Vancouver-based Hillcrest raised the bar in the EV power inverter industry, eliminating traditional trade-offs regarding heat generation and electromagnetic compatibility (“EMC”) that have plagued engineers for years. The company uses a combination of hardware and software to unlock higher switching frequencies resulting in improved power system performance and reliability without compromising efficiency.

This is the type of technology that the average driver won’t understand except for if it didn’t exist. Batteries in electric vehicles store energy as direct current (“DC”). While DC may be ideal for powering certain things, it absolutely is not ideal for the motors in EVs. As a matter of science, DC is incapable of the smoothness and predictability of a motor under rapid changes in voltage. AC (alternative current) is required, and the traction inverter is what converts the energy from DC to AC.

Conventional traction inverters are a staple of EVs. Hillcrest has developed a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements. Hillcrest’s flagship commercial prototype is a 250 kW|800V Hillcrest SiC high efficiency traction inverter that is ideal for electrification. While EVs are the low hanging fruit and a massive market opportunity, Hillcrest’s inverters have applications across an array of motors, generators, and throughout the renewable energy space.

An inverter is part-and-parcel to grid connected wind and solar power systems, energy storage, and EV chargers. In this case, the inverter converts the AC input from the grid/charging station to the DC output needed by the EV’s battery, which then, in turn, converts the energy again to power the vehicle. Against this backdrop, it is not hard to understand why the global inverter market is expected to reach $95 billion by 2028.

With its flagship inverter setting a new standard for traction inverters, Hillcrest is forecasting a transformational 2023 for the company, including proof-of-concept testing for an enhanced powertrain solution and a novel multi-level inverter technology. Furthermore, proof-of-concept testing is expected to be completed on a grid-tied inverter, as the company pushes for both horizontal and vertical expansion of its proprietary technology.

“Our near-term objective is to engage up to two additional EV customers and ramp up new customer agreements for our grid-tied renewable energy generation and Energy Storage System (‘ESS’) segments,” said Don Currie, Hillcrest CEO in a recent PR. “Combined, we believe these development and commercialization activities will position us well to secure commitments for commercial revenues by the end of the year,” he concluded.

For more information, visit the company’s website at www.HillcrestEnergy.tech.

NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF